Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q1 FY2022 Earnings Presentation
12 slides from Gland Pharma's earnings presentation, Jul 21, 2021
Slide 1: Gland Pharma Limited Financial Results Q1 FY22
Gland Pharma Limited Financial Results Q1’FY22 21st July 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 3: Financial Highlights (1/3)
Financial Highlights (1/3) Sustained business performance despite operational challenges Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn) (INR Mn / %) 4,981 11,539 4,981 11,539 4,447 3,749 8,877 41% 8,842 49% 41% 40% Q1 FY21 Q1 FY22 Q4 FY21 Q1 FY22 Q1 FY21 Q1 FY22 Q4 FY21 Q1 FY22 PBT
Slide 4: Financial Highlights (2/3)
Financial Highlights (2/3) Balance sheet continues to remain strong while CapEx remains in line with growth plans Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 62,897 59,032 12,250 12,250 30,058 30,017 30,574 30,533 50,647 46,782 Mar'21 Jun'21 Mar'21 Jun'21 Networth Fresh iss
Slide 5: Financial Highlights (3/3)
Financial Highlights (3/3) Focus on Capital efficiency and healthy return ratios Asset Turnover Ratio (1)(2) ROCE (ex-cash)(3) / ROCE (4) / RONW (5) (%) 3.6 3.1 49% 2.8 42% 32% 35% 23% 21% 0.8 33% 0.7 0.7 23% 21% (8) (8) Total asset turnover Fixed asset turnover Q1 FY21 FY21 Q1 FY22 Q1 FY21 FY21 Q1
Slide 6: P&L Highlights
P&L Highlights (INR Mn) YoY QoQ Particulars Q1 FY22 Q1 FY21 Q1 FY22 Q4 FY21 FY21 growth growth Revenue From operations 11,539 8,842 31% 11,539 8,877 30% 34,629 Other Income 618 321 93% 618 473 31% 1,348 Total income 12,157 9,163 33% 12,157 9,350 30% 35,977 Gross Margin(1) 6,174 5,643 9% 6,174 4,962
Slide 7: USA, Europe, Canada and Australia (Core Markets)
USA, Europe, Canada and Australia (Core Markets) Revenue: Q1 FY22: Rs. 7,042 Mn YoY Growth: 16% We delivered a strong performance with growth in existing products including Micafungin, Enoxaparin, Heparin, Dexmedetomidine among others and new prod- Core Markets (1) uct launches. It was also an imp
Slide 8: Rest of the World Markets
Rest of the World Markets Strong momentum during the first quarter in line with Q1 FY22: Rs. 2,227 Mn YoY Growth: 51% our focus on increased contribution from Rest of the world markets sales as was observed in FY21 Rest of the World Markets This has been driven by new partnerships and increased
Slide 9: India (Domestic Market)
India (Domestic Market) Domestic market sales received strong demand during Q1 FY22: Rs. 2,270 Mn the quarter accounting to 77% y-o-y growth YoY Growth: 77% The new capacities being made available for the India (Domestic Market) domestic market has helped ramp up volume growth in the core portfo
Slide 10: Near Term Focus Areas
Near Term Focus Areas Focus on achieving a diverse product mix offering products at various stages of their lifecycle as well as a robust product pipeline Commercialization of fill-finish vaccine manufacturing capacity and capability building on vaccine drug substance manufacturing. We also look t
Slide 11: Responding to COVID-19
Responding to COVID-19 To ensure health and safety of employees and their family, vaccination drives were conducted at corporate office and manufacturing facilities We put in adequate safeguards by taking precautionary measures; social distancing, workplace fumigation and sanitization across all
Slide 12: GLAND
Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District Hyder